Damora Therapeutics, Inc. (DMRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Damora Therapeutics, Inc. (DMRA) has a cash flow conversion efficiency ratio of 0.002x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($566.00K) by net assets ($240.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View DMRA stock price for real-time trading data and today's change.
Damora Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Damora Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Damora Therapeutics, Inc. (DMRA) market capitalisation for the company's overall valuation and market capitalisation.
Damora Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Damora Therapeutics, Inc. ranked by their cash flow conversion efficiency. Also see DMRA total assets for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Telkom
JSE:TKG
|
0.176x |
|
Dalian Huarui Heavy Industry Group Co Ltd
SHE:002204
|
-0.016x |
|
Sunvim Group Co Ltd
SHE:002083
|
0.021x |
|
Uniqure NV
NASDAQ:QURE
|
-0.072x |
|
GigaCloud Technology Inc Class A Ordinary Shares
NASDAQ:GCT
|
0.132x |
|
NCAB Group
ST:NCAB
|
0.199x |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
-1.863x |
|
PROG Holdings Inc
NYSE:PRG
|
0.222x |
Annual Cash Flow Conversion Efficiency for Damora Therapeutics, Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Damora Therapeutics, Inc. from 2018 to 2025. Review Damora Therapeutics, Inc. leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $240.38 Million | $-6.73 Million | -0.028x | +97.83% |
| 2024-12-31 | $14.47 Million | $-18.62 Million | -1.287x | -12.72% |
| 2023-12-31 | $32.33 Million | $-36.91 Million | -1.142x | -64.22% |
| 2022-12-31 | $61.75 Million | $-42.93 Million | -0.695x | -55.80% |
| 2021-12-31 | $117.22 Million | $-52.31 Million | -0.446x | -93.30% |
| 2020-12-31 | $165.49 Million | $-38.20 Million | -0.231x | +42.10% |
| 2019-12-31 | $48.47 Million | $-19.33 Million | -0.399x | +10.71% |
| 2018-12-31 | $30.66 Million | $-13.69 Million | -0.447x | -- |
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to u… Read more